Omalizumab effective for chronic spontaneous urticaria

February 13, 2018

(HealthDay)—Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria (CSU), according to a study published online Feb. 5 in the International Journal of Dermatology.

Nikolaos Syrigos, M.D., from Sotiria General Hospital in Athens, Greece, and colleagues retrospectively evaluated from 20 (mean age 54.5 years; 75 percent women) with refractory CSU in order to assess correlations between demographic, clinical, and laboratory characteristics and omalizumab treatment outcomes.

The researchers found that mean disease duration before omalizumab administration was 21.8 months. All patients responded favorably to omalizumab after one to five doses, with 85 percent of patients having a complete response. The remaining three patients had well-controlled disease after omalizumab treatment. In 30 percent of patients, the best response to omalizumab was achieved after interval administration of a nine-day course of methylprednisolone (total dose of 188 mg). A shorter disease duration before initiation of omalizumab was significantly correlated with late response to omalizumab (after three-month treatment).

"In the present series, , either alone or in combination with a short-term course of corticosteroids, was highly effective in resolution of refractory CSU," the authors write.

Explore further: Intranasal omalizumab does not increase serum IgE levels

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Intranasal omalizumab does not increase serum IgE levels

November 22, 2017
(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Omalizumab effective for chronic spontaneous urticaria

March 31, 2016
(HealthDay)—Omalizumab is effective in patients with moderate-to-severe chronic spontaneous urticaria (CSU) symptoms and angioedema unresponsive to high doses of antihistamine treatment, according to a study published online ...

Omalizumab protects against early, late allergic responses

June 9, 2017
(HealthDay)—For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.

Markers that predict omalizumab response identified

May 2, 2016
(HealthDay)—Baseline serum periostin levels and levels of serum free immunoglobulin E (IgE) during treatment follow-up may be useful in assessing response to omalizumab treatment for asthma, according to a study published ...

Asthma drug helps patients with skin disorder

April 7, 2017
Patients who develop itchy wheals in response to cold or friction benefit from treatment with omalizumab, a drug normally used to treat asthma. Two separate clinical studies, conducted by researchers from Charité - Universitätsmedizin ...

Omalizumab decreases colds in inner-city children with asthma, study reports

March 6, 2016
Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology ...

Recommended for you

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018
Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access ...

Protecting cell powerhouse paves way to better treatment of acute kidney injury

December 6, 2018
For the first time, scientists have described the body's natural mechanism for temporarily protecting the powerhouses of kidney cells when injury or disease means they aren't getting enough blood or oxygen.

New study uncovers why Rift Valley fever is catastrophic to developing fetuses

December 5, 2018
Like Zika, infection with Rift Valley fever virus can go unnoticed during pregnancy, all the while doing irreparable—often lethal—harm to the fetus. The results of a new study, led by researchers at the University of ...

Study highlights potential role of bioaerosol sampling to address airborne biological threats

December 5, 2018
As a leading global city with a high population density, Singapore is vulnerable to the introduction of biological threats. Initiating an early emergency response to such threats calls for the rapid identification of the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.